Riskpilot← Back to searchSign inGet full accessMEDFOUR AB
ABActiveOrg 5590089024Nockebyvägen 68Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20153 employees
Revenue 2025
SEK 26,7M
+15% vs 2024
EBITDA margin
13.3%
+81% vs 2024
Equity ratio
52.9%
Financial strength
Net profit 2025
SEK 2,8M
+86% vs 2024
| Revenue | SEK 26,7M | +15% |
| EBITDA | SEK 3,5M | +81% |
| Net profit | SEK 2,8M | +86% |
| Total assets | SEK 8,1M | +9% |
| Equity | SEK 4,3M | +70% |
| Employees | 3 | — |
Legal name
MEDFOUR AB
Org number
5590089024
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
26 mars 2015
Share capital
SEK 50 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva handel, export och import av medicinsk utrustning, konsultationsverksamhet inom ekonomi och marknadsföring samt förvalta fastigheter, aktier och andra värdepapper ävensom idka därmed förenlig verksamhet.
Address
Nockebyvägen 68
Email
jonas.nobel@medfour.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 14 098 | 15 655 | 16 812 | 23 286 | 26 729 |
| Staff expenses | — | — | −1 879 | −2 571 | −2 724 |
| EBITDA | 341 | 798 | 1 050 | 1 958 | 3 547 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 341 | 798 | 1 050 | 1 958 | 3 547 |
| Net financials | −36 | −73 | −58 | −74 | −40 |
| Profit before tax | 305 | 752 | 1 036 | 1 884 | 3 507 |
| Tax | −67 | −157 | −218 | −392 | −732 |
| Net profit | 238 | 595 | 818 | 1 493 | 2 775 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 314 | 4 401 | 5 253 | 7 481 | 8 123 |
| Equity | 816 | 1 411 | 1 629 | 2 522 | 4 297 |
| Long-term debt | 407 | 0 | 15 | 0 | — |
| Short-term debt | 3 021 | 2 947 | 3 609 | 4 959 | 3 827 |
| Total debt | 3 428 | 2 947 | 3 624 | 4 959 | 3 827 |
EBITDA margin
13.3%
This company
15.8%
Market median
-16% vs market
20212025
Equity ratio
52.9%
This company
38.2%
Market median
+38% vs market
20212025
Return on equity
64.6%
This company
18.4%
Market median
+251% vs market
20212025
Net profit margin
10.4%
This company
8.1%
Market median
+28% vs market
20212025
Asset turnover
3.29×
This company
1.12×
Market median
+194% vs market
20212025
Debt / equity
0.89×
This company
0.62×
Market median
+44% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MH Auditor Substitute | Auditor Substitute | 2021 |
| Audit | 2021 | |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2021 | |
| Chairman | 2021 | |
| Deputy Board Member | 2021 | |
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MEDFOUR AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Helena Fälton Björkman | Auditor Substitute | 0 companies |
| Kenneth Raine Christer Svensson | Audit | 0 companies |
| Anna Isabell Nachtweij | Deputy Board Member | 0 companies |
| Jonas Henrik Nobel | Chairman | 0 companies |
| Maria Elisabet Elin Nobel | Deputy Board Member | 0 companies |
| Jakob Lars Edvard Nachtweij | Board of Directors | 0 companies |